Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.

Autor:	Lanzoni G; Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, Florida, USA.; Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, Florida, USA., Linetsky E; Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, Florida, USA.; Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA., Correa D; Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, Florida, USA.; Department of Orthopedics, UHealth Sports Medicine Institute, University of Miami Miller School of Medicine, Miami, Florida, USA., Messinger Cayetano S; Division of Biostatistics, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida, USA., Alvarez RA; Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.; University of Miami Health System, Miami, Florida, USA., Kouroupis D; Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Alvarez Gil A; Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Poggioli R; Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Ruiz P; Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA., Marttos AC; Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.; University of Miami Health System, Miami, Florida, USA.; Jackson Health System, Miami, Florida, USA., Hirani K; Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, Florida, USA.; Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA., Bell CA; Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA., Kusack H; Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA., Rafkin L; Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Baidal D; Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, Florida, USA.; Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.; University of Miami Health System, Miami, Florida, USA., Pastewski A; Jackson Health System, Miami, Florida, USA., Gawri K; Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.; University of Miami Health System, Miami, Florida, USA., Leñero C; Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Mantero AMA; Division of Biostatistics, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida, USA., Metalonis SW; Division of Biostatistics, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida, USA., Wang X; Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Roque L; Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Masters B; Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Kenyon NS; Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Ginzburg E; Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.; University of Miami Health System, Miami, Florida, USA.; Jackson Health System, Miami, Florida, USA., Xu X; Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Tan J; The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, People's Republic of China., Caplan AI; Skeletal Research Center, Case Western Reserve University, Cleveland, Ohio, USA., Glassberg MK; University of Arizona College of Medicine, Tucson, Arizona, USA., Alejandro R; Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, Florida, USA.; Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.; University of Miami Health System, Miami, Florida, USA., Ricordi C; Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, Florida, USA.; Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.
Jazyk:	angličtina
Zdroj:	Stem cells translational medicine [Stem Cells Transl Med] 2021 May; Vol. 10 (5), pp. 660-673. Date of Electronic Publication: 2021 Jan 05.
DOI:	10.1002/sctm.20-0472
Abstrakt:	Acute respiratory distress syndrome (ARDS) in COVID-19 is associated with high mortality. Mesenchymal stem cells are known to exert immunomodulatory and anti-inflammatory effects and could yield beneficial effects in COVID-19 ARDS. The objective of this study was to determine safety and explore efficacy of umbilical cord mesenchymal stem cell (UC-MSC) infusions in subjects with COVID-19 ARDS. A double-blind, phase 1/2a, randomized, controlled trial was performed. Randomization and stratification by ARDS severity was used to foster balance among groups. All subjects were analyzed under intention to treat design. Twenty-four subjects were randomized 1:1 to either UC-MSC treatment (n = 12) or the control group (n = 12). Subjects in the UC-MSC treatment group received two intravenous infusions (at day 0 and 3) of 100 ± 20 × 10 6 UC-MSCs; controls received two infusions of vehicle solution. Both groups received best standard of care. Primary endpoint was safety (adverse events [AEs]) within 6 hours; cardiac arrest or death within 24 hours postinfusion). Secondary endpoints included patient survival at 31 days after the first infusion and time to recovery. No difference was observed between groups in infusion-associated AEs. No serious adverse events (SAEs) were observed related to UC-MSC infusions. UC-MSC infusions in COVID-19 ARDS were found to be safe. Inflammatory cytokines were significantly decreased in UC-MSC-treated subjects at day 6. Treatment was associated with significantly improved patient survival (91% vs 42%, P = .015), SAE-free survival (P = .008), and time to recovery (P = .03). UC-MSC infusions are safe and could be beneficial in treating subjects with COVID-19 ARDS. (© 2021 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals LLC on behalf of AlphaMed Press.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text